Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 4/20 | 0.43 |
| ▸ | AR | P10275 | 6/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10075680 | 0.91 | CYP11B2 (0.43) | CYP11B2ARCYP11B1ACACBACACA | |
| SCHEMBL10075681 | 0.82 | AR (0.43) | CYP11B2ARCYP11B1 | |
| SCHEMBL18994017 | 0.73 | AR (0.43) | CYP11B2AR | |
| SCHEMBL333430 | 0.72 | AR (0.55) | AR | |
| SCHEMBL333429 | 0.72 | AR (0.55) | AR | |
| SCHEMBL10075362 | 0.72 | CYP11B2 (0.43) | CYP11B2ARCYP11B1 | |
| SCHEMBL13480349 | 0.70 | CYP11B2 (0.32) | CYP11B2 | |
| SCHEMBL10075682 | 0.68 | AR (0.41) | CYP11B2ARCYP11B1 | |
| SCHEMBL10075912 | 0.68 | AR (0.44) | CYP11B2AR | |
| SCHEMBL332212 | 0.68 | AR (0.49) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097730-B2 | Bicyclic heterocycles useful as selective androgen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-17 | — | — | US | disclosed |
| US-20100160330-A1 | NOVEL BICYCLIC HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ZHANG XUQING | 2010-06-24 | — | — | US | disclosed |
| US-7626036-B2 | 4-(3a-Methyl-1,3-dioxo-5-trifluoromethyl-3a,4-dihydro-3H-1l4-thia-2,6,6a-triaza-pentalen-2-yl)-2-trifluoromethyl-benzonitrile; anticarcinogenic agents; prostate glands; benign prostatic hyperplasia; alopecia; eating disorders; mammary glands; acne; AIDS; cachexia; male contraceptives; sexual disorders | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160330-A1 | NOVEL BICYCLIC HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, NR5A1, FSHR | CYP11B2 18/4885AR 1/4885CYP11B1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.